Total mortality, but not sudden cardiac death, lower by wearable cardioverter-defibrillator in the immediate post-MI period with low EF3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL. USA - Jeffrey Olgin (San Francisco, CA, USA
ACC 2018 The randomised VEST trial examined whether a wearable defibrillator in the first three months after MI in patients with LVEF <35% lowered the early mortality risk.
This 3-minute education provides a summary of just presented scientific data, recorded during the ACC 2018. The objective is to provide a brief commentary and potential implications of these findings.
Jeffrey Olgin, MD is a cardiologist and electrophysiologist at UCSF Medical Center in San Francisco, CA, USA.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.